Trial NCT02259348

View at ClinicalTrials.gov 
Org. Study IDs: REFNK1
Secondary IDs: NCI-2014-01925

Last trial update was posted on 2017-05-30

MeSH Interventions

Aldesleukin Cyclophosphamide Fludarabine Fludarabine phosphate Interleukin-2 Mechlorethamine Melphalan Rituximab Thiotepa

MeSH Conditions

Hematologic Neoplasms Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Myelomonocytic, Juvenile Lymphoma, Non-Hodgkin Myelodysplastic Syndromes Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Preleukemia Sarcoma, Myeloid

Other Conditions

Acute Lymphoblastic Leukemia (ALL) Acute Myeloid Leukemia (AML) Chronic Myelogenous Leukemia (CML) Juvenile Myelomonocytic Leukemia (JMML) Myelodysplastic Syndrome (MDS) Myeloid Sarcoma Non-Hodgkin Lymphoma (NHL)

Stopping Reasons

Investigator's decision.

Limitations And Caveats

The trial was terminated early due to investigator's decision.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID